Incorporating Depression Screening into Diabetes Clinics across the T1DX Learning Collaborative

Objective: Depression contributes to suboptimal health outcomes amongst people with type 1 diabetes (T1D). The ADA standards of care recommend regular psychosocial screening, however these guidelines are not universally implemented. Aim: Demonstrate feasibility of expanding depression screening acro...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes (New York, N.Y.) Vol. 67; no. Supplement_1
Main Authors:	MAJIDI, SHIDEH, JOLLY, MARY C., ALONSO, GUY T., BUCKINGHAM, DON A., CABRERA, ALYSSA B., CLEMENTS, MARK A., GARRITY, ASHLEY, GIBBS, KATE A., GLICK, BETHANY, MING HONG, K., KAMBOJ, MANMOHAN K., LAMBERT, KATHRYN L., LEE, JOYCE, NADKARNI, PRASHANT V., MCDONOUGH, RYAN, OHMER, AMY L., RIOLES, NICOLE, STANEK, KELLY R., THOMAS, SARAH, WEINSTOCK, RUTH S., CORATHERS, SARAH
Format:	Journal Article
Language:	English
Published:	01-07-2018
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objective: Depression contributes to suboptimal health outcomes amongst people with type 1 diabetes (T1D). The ADA standards of care recommend regular psychosocial screening, however these guidelines are not universally implemented. Aim: Demonstrate feasibility of expanding depression screening across clinics in the national T1D Exchange Learning Collaborative (T1DX-LC) using a quality improvement (QI) approach. Methods: Six clinics in T1DX-LC participated in bi-monthly calls and three learning sessions for depression screening. Sites shared existing resources and used QI methodology to design iterative plan-do-study-act cycles to develop or refine existing processes and adopt interventions in their respective contexts around the following themes: 1) consistent screening and referral criteria, 2) integration of screening into work flow, 3) acceptance from families and staff, 4) adequate social work and psychology referral resources, and 5) incorporation of health information technology. Results: Screening increased from baseline of 10% across sites to 60% of eligible patients at all sites over 18 months (Figure). Discussion: Through the T1DX-LC, a network of centers were successful at completing depression screening in alignment with ADA standards of care. Sites expanded screening to individuals with type 2 diabetes and additional centers are joining the screening intervention. Disclosure S. Majidi: None. M.C. Jolly: None. G.T. Alonso: None. D.A. Buckingham: None. A.B. Cabrera: None. M.A. Clements: Speaker's Bureau; Self; Medtronic. Advisory Panel; Self; Glooko, Inc.. A. Garrity: None. K.A. Gibbs: None. B. Glick: None. K. Hong: None. M.K. Kamboj: None. K.L. Lambert: None. J. Lee: Consultant; Self; Unitio. P.V. Nadkarni: None. R. McDonough: None. A.L. Ohmer: None. N. Rioles: None. K.R. Stanek: None. S. Thomas: None. R.S. Weinstock: Research Support; Self; Medtronic MiniMed, Inc., Mylan, Kowa Pharmaceuticals America, Inc., Diasome Pharmaceuticals, Inc., Calibra Medical, Dexcom, Inc., Ultradian Diagnostics LLC., JAEB Center For Health Research, JDRF, National Institute of Diabetes and Digestive and Kidney Diseases. S. Corathers: None.
ISSN:	0012-1797 1939-327X
DOI:	10.2337/db18-1309-P